It has been shown that interfering with KDM5A expression led to apoptosis, inhibited cell proliferation, and promoted the sensitivity of cancer cells to Gefitinib, accompanied by upregulation of BAX protein expression and downregulation of Bcl-2 protein expression in LUAD. This evidence concerns the gene KDM5A and cancer.